Mostrar el registro sencillo del ítem

dc.contributorAl Enzi, S.A.EN
dc.contributorIsmail, W.A.EN
dc.contributorAlsurayei, S.A.EN
dc.contributorIsmail, A.E.EN
dc.date.accessioned2014-06-17T09:52:07Z
dc.date.available2014-06-17T09:52:07Z
dc.date.issued2011EN
dc.identifier.issn1020-3397EN
dc.identifier.otherhttp://applications.emro.who.int/emhj/V17/08/17_8_2011_0669_0678.pdfEN
dc.identifier.urihttp://www.who.int/iris/handle/10665/118282
dc.description669-678EN
dc.description.abstractFew studies have been conducted in the Eastern Mediterranean region on chronic hepatitis C virus [‎HCV]‎ infection with reference to genotypes. We investigated the response to standard combination therapy [‎pegylated interferon/ribavirin]‎ of different genotypes of HCV in Kuwaiti patients and factors that could be associated with sustained virological response [‎SVR]‎. The records of all Kuwaiti patients treated for chronic HCV between January 2003 and May 2009 were retrospectively identified and reviewed. Of 108 patients studied, 27.8% were infected with genotype 1, 25.0% with genotype 3 and 47.2% with genotype 4. Overall, 64.8% of patients achieved SVR, 25.9%, were non-responders and 9.3% were relapsers. Baseline viral load and alanine aminotransferase level in addition to early virological response to pegylated interferon-based therapy may serve as a decision tool for clinicians to identify patients who are unlikely to achieve SVREN
dc.language.isoenEN
dc.subjectInterferon-alphaEN
dc.subjectPolyethylene GlycolsEN
dc.subjectRibavirinEN
dc.subjectRetrospective StudiesEN
dc.subjectTreatment OutcomeEN
dc.subjectGenotypeEN
dc.subjectViral LoadEN
dc.subject.meshHepatitis C, ChronicEN
dc.titlePeginterferon alfa-2b and ribavirin therapy in Kuwaiti patients with chronic hepatitis C virus infectionEN
dc.relation.ispartofjournalEMHJ - Eastern Mediterranean Health Journal, 17 (‎8)‎, 669-678, 2011


Ficheros en el ítem

Thumbnail

Este ítem aparece en la(‎s)‎ siguiente(‎s)‎ colección(‎ones)‎

Mostrar el registro sencillo del ítem